Functional Beverage Market Expected to Reach $179.26 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Should l Buy CGC?
Source: Newsfilter
- Market Growth Potential: The global functional beverage market is projected to reach $179.26 billion by 2026, driven by health-conscious consumers shifting towards low-sugar, transparent-label products, creating significant market opportunities for related companies.
- Doseology New Product Pilot: Doseology Sciences initiated pilot production of non-nicotine, caffeine-based energy pouches in January 2026, utilizing a portable, non-liquid delivery method aimed at providing controlled energy release, aligning with modern consumer demands for functional beverages.
- Canopy Growth Financial Restructuring: Canopy Growth successfully extended its debt maturities to 2031 through strategic refinancing transactions, expected to secure approximately C$425 million in cash flow, enhancing the company's liquidity and competitive position in the market.
- Splash Beverage Joint Venture Expansion: Splash Beverage Group entered the rapidly growing THC beverage market through a joint venture with BAAD Ventures, planning to expand into six new markets, leveraging both parties' distribution networks and brand-building expertise to increase market share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGC
Wall Street analysts forecast CGC stock price to rise
4 Analyst Rating
1 Buy
2 Hold
1 Sell
Hold
Current: 0.857
Low
1.03
Averages
2.52
High
5.90
Current: 0.857
Low
1.03
Averages
2.52
High
5.90
About CGC
Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Canopy Growth Faces Pressure as U.S. Marijuana Legalization Remains Unlikely
- Stock Price Decline: Canopy Growth's stock has dropped 27% this year and is trading near its 52-week low, reflecting severe investor pessimism about its future prospects and resulting in a significant loss of confidence.
- Poor Financial Performance: In the last three months of 2025, the company reported net revenue of CAD 74.5 million, flat year-over-year, while incurring an operating loss of CAD 26.4 million, which is higher than the CAD 23.8 million loss from the previous year, indicating a continued deterioration in profitability.
- Intense Market Competition: Although marijuana is legalized in Canada, Canopy Growth faces fragmentation and low margins due to fierce competition and market restrictions, making it difficult for the company to dominate the industry.
- Bleak Future Outlook: With hopes for marijuana legalization in the U.S. appearing dim, Canopy Growth's market cap stands at around $380 million, a stark decline from over $12 billion five years ago, prompting investors to carefully consider their positions in the stock.
See More
Apollo Named Best Medical Cannabis Clinic by Toronto Star Readers' Choice Awards
- Patient Trust Recognition: Apollo Cannabis Clinics has been voted Best Medical Cannabis Clinic in the 2025 Toronto Star Readers' Choice Awards, reflecting the high level of trust patients place in its care, thereby reinforcing Canopy Growth's leadership in the medical cannabis sector.
- Accessible Medical Services: Apollo offers free virtual medical cannabis consultations nationwide without referral requirements, providing personalized treatment plans and ongoing support, which has helped thousands of Canadians manage chronic pain, anxiety, and other complex conditions.
- CEO's Commitment: Canopy Growth CEO Luc Mongeau emphasized that the recognition of Apollo stems from a genuine commitment to positive patient outcomes, making this trust strategically significant for the company's future business development.
- Innovative Products and Services: Canopy Growth delivers innovative products through various owned brands, and Apollo's success not only enhances brand image but also lays a foundation for the company's expansion in the medical cannabis market, showcasing its determination to improve patients' quality of life.
See More
Canopy Growth Launches New Brand Deelish for Everyday Consumers
- Brand Launch: Canopy Growth has introduced a new brand, Deelish, designed for everyday consumers, offering flower with 27%-33% THC and pre-rolls with 26%-32% THC, aimed at meeting the demand for high-potency products in the market.
- Product Diversity: The Deelish product line includes four SKUs across various formats, such as 28g Whole Flower and 2x1g pre-rolls, ensuring consumers have access to a diverse range of options, thereby enhancing brand appeal.
- Market Positioning: Focused on the value segment, CEO Luc Mongeau stated that Deelish aims to deliver high-potency products at reasonable prices to align with consumer shopping habits, reflecting the evolving trends in the market.
- Regional Availability: Currently, Deelish products are available at select stores across Ontario and Alberta, marking Canopy Growth's further expansion in the Canadian market and strengthening its position in a competitive landscape.
See More
Canopy Growth Stock Continues to Decline
- Stock Price Decline: Canopy Growth's stock has dropped 27% this year and is trading near its 52-week low, indicating ongoing struggles in a highly competitive market that have severely undermined investor confidence.
- Profitability Challenges: In the last quarter of 2025, the company reported net revenue of CAD 74.5 million, flat year-over-year, while operating losses increased from CAD 23.8 million to CAD 26.4 million, highlighting difficulties in cost management.
- Bleak Market Outlook: Despite legalization in Canada, Canopy Growth faces significant challenges in achieving profitability due to fierce competition and market restrictions, with its stock plummeting over 99% in the past five years, leading to a pessimistic outlook from investors.
- Hope for Legal Reform: The company's future hinges on the potential legalization of marijuana in the U.S., which could open up substantial market opportunities, but this prospect remains distant, prompting investors to approach with caution.
See More
David Männer Appointed Managing Director of Storz & Bickel
- Leadership Transition: David Männer will succeed Jürgen Bickel as Managing Director of Storz & Bickel effective April 1, 2026, following Bickel's 25 years of transformative leadership that established the company as a global leader in vaporization technology, indicating stability and continuity in the company's leadership.
- Industry Benchmark: Since its founding in 2001, Storz & Bickel has set the standard for innovation, product quality, and design, earning ISO 13485 certification and the Dr. Rudolf Eberle Prize, which underscores its strong competitive position in the market as a benchmark for vapor quality.
- Future Development: Incoming Managing Director Männer, a 14-year veteran of the company with deep operational knowledge and leadership skills, is expected to continue driving the company's expansion in the U.S. market and innovation efforts, further solidifying Storz & Bickel's market position.
- Strategic Vision: Canopy Growth CEO Luc Mongeau stated that Männer's appointment will accelerate Storz & Bickel's growth, reflecting the company's ambitions in the global vaporization market and aiming to enhance brand influence through ongoing innovation.
See More
Canopy Growth and Sarepta Face Dismal Prospects
- Canopy Growth's Financial Struggles: In Q3 of fiscal 2026, Canopy Growth reported flat net revenue of CA$75 million ($54.6 million) year-over-year, with a 49% improvement in the bottom line overshadowed by a net loss per share of CA$0.18 ($0.13), indicating ongoing financial distress.
- Regulatory Challenges in Cannabis: The cannabis industry is fraught with heavy regulation and uncertainty, making future legal changes and market responses unpredictable, which casts a shadow over Canopy Growth's prospects and warrants caution from investors.
- Sarepta Therapeutics' Drug Risks: Sarepta's Elevidys drug has faced significant challenges after causing the deaths of two patients due to liver failure; despite remedial actions, the company's Q4 2025 revenue fell 33% year-over-year to $442.9 million, reflecting worsening financial conditions.
- Clinical Trial Failures: As Sarepta seeks full approval for other DMD drugs, recent confirmatory trial results have failed to meet primary endpoints, exacerbating investor concerns about its future, with the stock plummeting 79% over the past year.
See More
Canopy Growth Faces Pressure as U.S. Marijuana Legalization Remains Unlikely
- Stock Price Decline: Canopy Growth's stock has dropped 27% this year and is trading near its 52-week low, reflecting severe investor pessimism about its future prospects and resulting in a significant loss of confidence.
- Poor Financial Performance: In the last three months of 2025, the company reported net revenue of CAD 74.5 million, flat year-over-year, while incurring an operating loss of CAD 26.4 million, which is higher than the CAD 23.8 million loss from the previous year, indicating a continued deterioration in profitability.
- Intense Market Competition: Although marijuana is legalized in Canada, Canopy Growth faces fragmentation and low margins due to fierce competition and market restrictions, making it difficult for the company to dominate the industry.
- Bleak Future Outlook: With hopes for marijuana legalization in the U.S. appearing dim, Canopy Growth's market cap stands at around $380 million, a stark decline from over $12 billion five years ago, prompting investors to carefully consider their positions in the stock.
See More
Apollo Named Best Medical Cannabis Clinic by Toronto Star Readers' Choice Awards
- Patient Trust Recognition: Apollo Cannabis Clinics has been voted Best Medical Cannabis Clinic in the 2025 Toronto Star Readers' Choice Awards, reflecting the high level of trust patients place in its care, thereby reinforcing Canopy Growth's leadership in the medical cannabis sector.
- Accessible Medical Services: Apollo offers free virtual medical cannabis consultations nationwide without referral requirements, providing personalized treatment plans and ongoing support, which has helped thousands of Canadians manage chronic pain, anxiety, and other complex conditions.
- CEO's Commitment: Canopy Growth CEO Luc Mongeau emphasized that the recognition of Apollo stems from a genuine commitment to positive patient outcomes, making this trust strategically significant for the company's future business development.
- Innovative Products and Services: Canopy Growth delivers innovative products through various owned brands, and Apollo's success not only enhances brand image but also lays a foundation for the company's expansion in the medical cannabis market, showcasing its determination to improve patients' quality of life.
See More
Canopy Growth Launches New Brand Deelish for Everyday Consumers
- Brand Launch: Canopy Growth has introduced a new brand, Deelish, designed for everyday consumers, offering flower with 27%-33% THC and pre-rolls with 26%-32% THC, aimed at meeting the demand for high-potency products in the market.
- Product Diversity: The Deelish product line includes four SKUs across various formats, such as 28g Whole Flower and 2x1g pre-rolls, ensuring consumers have access to a diverse range of options, thereby enhancing brand appeal.
- Market Positioning: Focused on the value segment, CEO Luc Mongeau stated that Deelish aims to deliver high-potency products at reasonable prices to align with consumer shopping habits, reflecting the evolving trends in the market.
- Regional Availability: Currently, Deelish products are available at select stores across Ontario and Alberta, marking Canopy Growth's further expansion in the Canadian market and strengthening its position in a competitive landscape.
See More
Canopy Growth Stock Continues to Decline
- Stock Price Decline: Canopy Growth's stock has dropped 27% this year and is trading near its 52-week low, indicating ongoing struggles in a highly competitive market that have severely undermined investor confidence.
- Profitability Challenges: In the last quarter of 2025, the company reported net revenue of CAD 74.5 million, flat year-over-year, while operating losses increased from CAD 23.8 million to CAD 26.4 million, highlighting difficulties in cost management.
- Bleak Market Outlook: Despite legalization in Canada, Canopy Growth faces significant challenges in achieving profitability due to fierce competition and market restrictions, with its stock plummeting over 99% in the past five years, leading to a pessimistic outlook from investors.
- Hope for Legal Reform: The company's future hinges on the potential legalization of marijuana in the U.S., which could open up substantial market opportunities, but this prospect remains distant, prompting investors to approach with caution.
See More
David Männer Appointed Managing Director of Storz & Bickel
- Leadership Transition: David Männer will succeed Jürgen Bickel as Managing Director of Storz & Bickel effective April 1, 2026, following Bickel's 25 years of transformative leadership that established the company as a global leader in vaporization technology, indicating stability and continuity in the company's leadership.
- Industry Benchmark: Since its founding in 2001, Storz & Bickel has set the standard for innovation, product quality, and design, earning ISO 13485 certification and the Dr. Rudolf Eberle Prize, which underscores its strong competitive position in the market as a benchmark for vapor quality.
- Future Development: Incoming Managing Director Männer, a 14-year veteran of the company with deep operational knowledge and leadership skills, is expected to continue driving the company's expansion in the U.S. market and innovation efforts, further solidifying Storz & Bickel's market position.
- Strategic Vision: Canopy Growth CEO Luc Mongeau stated that Männer's appointment will accelerate Storz & Bickel's growth, reflecting the company's ambitions in the global vaporization market and aiming to enhance brand influence through ongoing innovation.
See More
Canopy Growth and Sarepta Face Dismal Prospects
- Canopy Growth's Financial Struggles: In Q3 of fiscal 2026, Canopy Growth reported flat net revenue of CA$75 million ($54.6 million) year-over-year, with a 49% improvement in the bottom line overshadowed by a net loss per share of CA$0.18 ($0.13), indicating ongoing financial distress.
- Regulatory Challenges in Cannabis: The cannabis industry is fraught with heavy regulation and uncertainty, making future legal changes and market responses unpredictable, which casts a shadow over Canopy Growth's prospects and warrants caution from investors.
- Sarepta Therapeutics' Drug Risks: Sarepta's Elevidys drug has faced significant challenges after causing the deaths of two patients due to liver failure; despite remedial actions, the company's Q4 2025 revenue fell 33% year-over-year to $442.9 million, reflecting worsening financial conditions.
- Clinical Trial Failures: As Sarepta seeks full approval for other DMD drugs, recent confirmatory trial results have failed to meet primary endpoints, exacerbating investor concerns about its future, with the stock plummeting 79% over the past year.
See More
